# Klaus Breiner

> Klaus Breiner is a Series A investor at Pureos Bioventures backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pureos Bioventures](https://shizune.co/investors/profile/pureos-bioventures)
- Location: Freienbach, Switzerland
- Total investments: 5
- Last investment: Sep 2022
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/klaus-breiner-3a73458

Klaus Breiner is a Series A investor at Pureos Bioventures in Freienbach focused on Biotechnology and Health Care. Klaus is a founding partner of Pureos and has been a venture capital investor since 2001, across different regions, companies stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Bio-pharmaceutical companies that Klaus has invested in include AM-Pharma, Alpex Pharma, CadencePharmaceuticals, Glycart Biotechnology, Hummingbird Bioscience, ImCheck Therapeutics and Vaximm. Before venture capital, Klaus was a researcher at ETH Zurich and a business consultant at Booz Allen & Hamilton. Klaus holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in molecular biology from the University of Heidelberg (ZMBH).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Health Care | 2 | 40% |
| Life Science | 2 | 40% |
| Therapeutics | 2 | 40% |
| Dental | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 20% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |
| Funding Round | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 2 | 40% |
| Germany | 1 | 20% |
| Switzerland | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tridek-One | Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and givethem a better life. | $16M | Venture - Series Unknown | Sep 15, 2022 |  |
| ImCheck Therapeutics | ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours. | $100M | Series C | Jun 13, 2022 |  |
| ImCheck Therapeutics | ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours. | $7.1M | Series B | Sep 15, 2020 |  |
| Natural Dental Implants | Replicate Dental Technologies is dedicated to developing a solution in changing single tooth replacement with a patented, patient-friendly product that does not require drilling or destroying healthy teeth. It offers a minimally-invasive, patented medical device for replacing teeth.The company was founded in 2009 and is headquartered in Dublin,Ireland. | $1.1M | Series A | Jun 11, 2014 |  |
| Vaximm | Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinicaltrials in 2011. | $8.5M |  | Jan 12, 2011 |  |

5 of 5 investments shown.

## Co-investors
- [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 2 deals together
- [AdBio partners](https://shizune.co/investors/profile/advent-france-biotechnology) — VC Fund, 1 deal together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 1 deal together
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 1 deal together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 1 deal together
- [Bioqube Ventures](https://shizune.co/investors/profile/bioqube-ventures) — VC Fund, 1 deal together

## About Pureos Bioventures

VC Fund · Küsnacht, Switzerland

Pureos Bioventures is a new venture capital fund located in Zurich to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats

4 contacts available at Pureos Bioventures.

| Name | Title | Profile |
| --- | --- | --- |
| Klaus Breiner | Managing Partner & Founding partner | https://shizune.co/investors/profile/klaus-breiner |
| Martin Münchbach | Managing Partner & Founding Partner | https://shizune.co/investors/profile/martin-mnchbach |
| Dominik Escher | Managing Partner & Founding partner | https://shizune.co/investors/profile/dominik-escher |
| Ximing Ding | Investment Manager | https://shizune.co/investors/profile/ximing-ding-d13b |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Klaus Breiner invest in?

Klaus Breiner invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Klaus Breiner last invest?

The most recent investment recorded for Klaus Breiner closed in Sep 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co